Innocan Pharma Set for the ThinkEquity Conference
Innocan Pharma Corporation, a trailblazer in chronic pain relief through its Liposomal CBD drug products, is preparing to make a notable appearance at the ThinkEquity Conference. This prominent event will take place on October 30, 2024, in New York City, bringing together a wide array of institutional investors and industry professionals dedicated to exploring the latest advancements in financial strategies and innovations.
Company Highlights Before the Conference
As Innocan prepares for this key outing, the company aims to spotlight its recent regulatory accomplishments, particularly the recent approval it secured from the U.S. Food and Drug Administration (FDA). This approval for a 505(2)(b) abbreviated pathway exemplifies Innocan's commitment to advancing its human health applications and further solidifying its position in the pharmaceutical arena. Additionally, the FDA granted a waiver for the sponsor fee and issued an Investigational New Animal Drug number (INAD), crucial for Innocan's expanding animal health applications.
CEO's Presentation Details
Iris Bincovich, the CEO of Innocan Pharma, is scheduled to present at 2 PM ET, in the Lotus Suite West during the conference. Alongside the presentation, members of the Innocan management team will also be engaging in one-on-one meetings with potential investors throughout the day, offering a unique opportunity for direct communication and discussions.
Understanding the ThinkEquity Conference
The ThinkEquity Conference serves as a vital platform for facilitating connections between companies and investors. Established by a team of professionals who have combined to raise over $50 billion in capital, the conference is recognized for its ability to convene major players in the market. Previous events have seen numerous company presentations and facilitated hundreds of one-on-one meetings, showcasing an environment ripe for business relationships and investor opportunities.
Innocan's Diverse Portfolio
As an innovator in both the pharmaceutical and wellness sectors, Innocan Pharma has developed a groundbreaking CBD-loaded liposome drug delivery system. This innovative platform ensures precise dosing and a controlled release of synthetic CBD, providing effective non-opioid solutions for pain management. Innocan is also dedicated to enhancing consumer health through its range of self-care and beauty products, aiming to promote a healthier lifestyle.
Contact Information for Further Inquiries
Innocan urges interested parties to reach out for additional information or inquiries. Iris Bincovich, the CEO, can be contacted directly through the following numbers: +1 5162104025, +972-54-3012842, +442037699377. For any inquiries through email, please contact info@innocanpharma.com.
Frequently Asked Questions
What is the ThinkEquity Conference?
The ThinkEquity Conference is an event that connects institutional investors and corporate clients to discuss innovations and financial strategies.
Who will present at the event?
Iris Bincovich, the CEO of Innocan Pharma, will present and represent the company during the conference.
What are Innocan’s key achievements recently?
Innocan recently gained FDA approval for its 505(2)(b) pathway, enhancing its capacity for pharmaceuticals and expanding into animal health.
How can investors engage with Innocan Pharma?
Investors can schedule one-on-one meetings with Innocan management during the conference for personalized discussions.
Where can I find more information about Innocan Pharma?
For comprehensive information about Innocan's products and advancements, visit their official website at www.innocanpharma.com.
